These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

304 related articles for article (PubMed ID: 30132336)

  • 1. Antiplatelet Therapy Bridging With Cangrelor in Patients With Coronary Stents: A Case Series.
    Bowman S; Gass J; Weeks P
    Ann Pharmacother; 2019 Feb; 53(2):171-177. PubMed ID: 30132336
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Platelet Inhibition With Cangrelor and Crushed Ticagrelor in Patients With ST-Segment-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention.
    Franchi F; Rollini F; Rivas A; Wali M; Briceno M; Agarwal M; Shaikh Z; Nawaz A; Silva G; Been L; Smairat R; Kaufman M; Pineda AM; Suryadevara S; Soffer D; Zenni MM; Bass TA; Angiolillo DJ
    Circulation; 2019 Apr; 139(14):1661-1670. PubMed ID: 30630341
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized Comparison of Oral P2Y
    Hochholzer W; Kleiner P; Younas I; Valina CM; Löffelhardt N; Amann M; Bömicke T; Ferenc M; Hauschke D; Trenk D; Neumann FJ; Stratz C
    JACC Cardiovasc Interv; 2017 Jan; 10(2):121-129. PubMed ID: 28104204
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antithrombotic Stewardship: Evaluation of Platelet Reactivity-Guided Cangrelor Dosing Using the VerifyNow Assay.
    Connery A; Ahuja T; Katz A; Arnouk S; Zhu E; Papadopoulos J; Rao S; Merchan C
    J Cardiovasc Pharmacol; 2024 May; 83(5):482-489. PubMed ID: 38335531
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cangrelor: a novel intravenous antiplatelet agent with a questionable future.
    Waite LH; Phan YL; Spinler SA
    Pharmacotherapy; 2014 Oct; 34(10):1061-76. PubMed ID: 25123696
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Periprocedural Outcomes According to Timing of Clopidogrel Loading Dose in Patients Who Did Not Receive P2Y
    Abtan J; Ducrocq G; Steg PG; Stone GW; Mahaffey KW; Gibson CM; Hamm CW; Price MJ; Prats J; Deliargyris EN; White HD; Harrington RA; Bhatt DL
    Circ Cardiovasc Interv; 2019 Mar; 12(3):e007445. PubMed ID: 30871355
    [TBL] [Abstract][Full Text] [Related]  

  • 7. What is the Role of Cangrelor in Patients Undergoing PCI?
    Droppa M; Geisler T
    Curr Vasc Pharmacol; 2018; 16(5):484-489. PubMed ID: 29345586
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacodynamic effects during the transition between cangrelor and prasugrel.
    Schneider DJ; Seecheran N; Raza SS; Keating FK; Gogo P
    Coron Artery Dis; 2015 Jan; 26(1):42-8. PubMed ID: 25089928
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and Safety of Cangrelor in Preventing Periprocedural Complications in Patients With Stable Angina and Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention: The CHAMPION PHOENIX Trial.
    Abtan J; Steg PG; Stone GW; Mahaffey KW; Gibson CM; Hamm CW; Price MJ; Abnousi F; Prats J; Deliargyris EN; White HD; Harrington RA; Bhatt DL;
    JACC Cardiovasc Interv; 2016 Sep; 9(18):1905-13. PubMed ID: 27659566
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of cangrelor and access site on ischaemic and bleeding events: insights from CHAMPION PHOENIX.
    Gutierrez JA; Harrington RA; Blankenship JC; Stone GW; Steg PG; Gibson CM; Hamm CW; Price MJ; Généreux P; Prats J; Deliargyris EN; Mahaffey KW; White HD; Bhatt DL;
    Eur Heart J; 2016 Apr; 37(14):1122-30. PubMed ID: 26400827
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intravenous antiplatelet therapies (glycoprotein IIb/IIIa receptor inhibitors and cangrelor) in percutaneous coronary intervention: from pharmacology to indications for clinical use.
    Capodanno D; Milluzzo RP; Angiolillo DJ
    Ther Adv Cardiovasc Dis; 2019; 13():1753944719893274. PubMed ID: 31823688
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacodynamic effects during the transition between cangrelor and ticagrelor.
    Schneider DJ; Agarwal Z; Seecheran N; Keating FK; Gogo P
    JACC Cardiovasc Interv; 2014 Apr; 7(4):435-42. PubMed ID: 24656538
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cangrelor in Percutaneous Coronary Intervention: Current Status and Perspectives.
    Alexopoulos D; Pappas C; Sfantou D; Lekakis J
    J Cardiovasc Pharmacol Ther; 2018 Jan; 23(1):13-22. PubMed ID: 29228817
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is There an Ideal Level of Platelet P2Y12-Receptor Inhibition in Patients Undergoing Percutaneous Coronary Intervention?: "Window" Analysis From the ADAPT-DES Study (Assessment of Dual AntiPlatelet Therapy With Drug-Eluting Stents).
    Kirtane AJ; Parikh PB; Stuckey TD; Xu K; Witzenbichler B; Weisz G; Rinaldi MJ; Neumann FJ; Metzger DC; Henry TD; Cox DA; Duffy PL; Brodie BR; Mazzaferri EL; Parvataneni R; Maehara A; Généreux P; Mehran R; Stone GW
    JACC Cardiovasc Interv; 2015 Dec; 8(15):1978-1987. PubMed ID: 26738669
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intravenous Antiplatelet Therapy Bridging in Patients Undergoing Cardiac or Non-Cardiac Surgery Following Percutaneous Coronary Intervention.
    Dargham BB; Baskar A; Tejani I; Cui Z; Chauhan S; Sum-Ping J; Weideman RA; Banerjee S
    Cardiovasc Revasc Med; 2019 Sep; 20(9):805-811. PubMed ID: 30579773
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcomes with cangrelor versus clopidogrel on a background of bivalirudin: insights from the CHAMPION PHOENIX (A Clinical Trial Comparing Cangrelor to Clopidogrel Standard Therapy in Subjects Who Require Percutaneous Coronary Intervention [PCI]).
    White HD; Bhatt DL; Gibson CM; Hamm CW; Mahaffey KW; Price MJ; Steg PG; Stone GW; Cortese B; Wilensky M; Deliargyris EN; Liu T; Prats J; Harrington RA
    JACC Cardiovasc Interv; 2015 Mar; 8(3):424-433. PubMed ID: 25703887
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cangrelor: A Review in Percutaneous Coronary Intervention.
    Keating GM
    Drugs; 2015 Aug; 75(12):1425-34. PubMed ID: 26201463
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rationale and design of the Cangrelor versus standard therapy to acHieve optimal Management of Platelet InhibitiON PHOENIX trial.
    Leonardi S; Mahaffey KW; White HD; Gibson CM; Stone GW; Steg GW; Hamm CW; Price MJ; Todd M; Dietrich M; Gallup D; Liu T; Skerjanec S; Harrington RA; Bhatt DL
    Am Heart J; 2012 May; 163(5):768-776.e2. PubMed ID: 22607853
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and efficacy of cangrelor, an intravenous, short-acting platelet inhibitor in patients requiring coronary artery bypass surgery.
    Firstenberg MS; Dyke CM; Angiolillo DJ; Ramaiahm C; Price M; Brtko M; Welsby I; Chandna H; Holmes DR; Voeltz M; Tummala P; Hutyra M; Manoukian SV; Prats J; Todd M; Liu T; Chronos N; Dietrich M; Montalescot G; Cannon LA; Topo EJ
    Heart Surg Forum; 2013 Apr; 16(2):E60-9. PubMed ID: 23625478
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of Ischemic and Bleeding Risks Associated With 2 Parenteral Antiplatelet Strategies Comparing Cangrelor With Glycoprotein IIb/IIIa Inhibitors: An Exploratory Analysis From the CHAMPION Trials.
    Vaduganathan M; Harrington RA; Stone GW; Deliargyris EN; Steg PG; Gibson CM; Hamm CW; Price MJ; Menozzi A; Prats J; Elkin S; Mahaffey KW; White HD; Bhatt DL
    JAMA Cardiol; 2017 Feb; 2(2):127-135. PubMed ID: 27902833
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.